Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

@article{Koulouridis2013DoseOE,
  title={Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.},
  author={Ioannis Koulouridis and Mansour Alfayez and Thomas A. Trikalinos and Ethan M. Balk and Bertrand L. Jaber},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2013},
  volume={61 1},
  pages={44-56}
}
BACKGROUND Targeting higher hemoglobin levels with erythropoiesis-stimulating agents (ESAs) to treat the anemia of chronic kidney disease (CKD) is associated with increased cardiovascular risk. STUDY DESIGN Metaregression analysis examining the association of ESA dose with adverse outcomes independent of target or achieved hemoglobin level. SETTING & POPULATION Patients with anemia of CKD irrespective of dialysis status. SELECTION CRITERIA FOR STUDIES We searched MEDLINE (inception to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
38 Citations
71 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease

  • FDA. Dru
  • http://www.fda.gov/Drugs/ DrugSafety/ucm259639…
  • 2011
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…